CAI vs ILMN
CAI: Caris Life Sciences delivers comprehensive molecular profiling and precision medicine insights to optimize oncology treatment and drug development. ILMN: Illumina provides the essential genetic sequencing and array platforms that power modern genomic research and clinical diagnostics.
Side-by-side fundamentals
| Metric | CAI | ILMN | Edge |
|---|---|---|---|
| Price as of 2026-08-24 close | $26.13 | $223.22 | |
| Market cap as of 2026-08-24 | $7.4B | $33.7B | |
| P/E as of 2026-08-24 | 71.24 | 41.49 | ILMN lower |
| PEG as of 2026-08-24 | 1.72 | 3.62 | CAI lower |
| Net margin as of 2026-08-24 | +10.6% | +18.4% | ILMN higher |
| Gross margin as of 2026-08-24 | +69.7% | +66.4% | CAI higher |
| Operating margin as of 2026-08-24 | +12.7% | +19.5% | ILMN higher |
| ROE as of 2026-08-24 | +18.8% | +31.1% | ILMN higher |
| ROA as of 2026-08-24 | +9.3% | +12.7% | ILMN higher |
| Debt / equity as of 2026-08-24 | 0.66 | 0.70 | CAI lower |
| Revenue growth (YoY) as of 2026-08-24 | +38.5% | +4.9% | CAI higher |
| Revenue CAGR (3y) SEC XBRL | +62.9% | -1.4% | CAI higher |
| Beta as of 2026-08-24 | 1.27 | 1.02 | |
| 1-year return as of 2026-08-24 close | -33.5% | +119.3% | ILMN higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.